Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1550-1560

  Lim, Philip K ^a   Bliss, Sarah A ^b   Patel, Shyam A ^a,b   Taborga, Marcelo ^a,d   Dave, Meneka A ^a   Gregory, Larissa A ^a   Greco, Steven J ^b   Bryan, Margarette ^a   Patel, Prem S ^c   Rameshwar, Pranela ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b The State University of New Jersey   (United States)

^c BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^d SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; STROMAL CELL DERIVED FACTOR 1;

ADULT; ARTICLE; BONE MARROW CELL; BONE MARROW METASTASIS; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; EXOSOME; GAP JUNCTION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA TRANSPORT; STROMA CELL; TUMOR CELL;

BLOTTING, WESTERN; BONE MARROW CELLS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHEMOKINE CXCL12; COCULTURE TECHNIQUES; FEMALE; GAP JUNCTIONS; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS;

EID: 79952219931     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2372     Document Type: Article

References (44)

1. Green BB, Taplin SH. Breast Cancer Screening Controversies. J Am Board Fam Pract 2003;16:233-41.
2. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 2007;1:160-71. (Pubitemid 47199130)
3. Habeck M. Bone-marrow analysis predicts breast-cancer recurrence. Mol Med Today 2000;6:256-7. (Pubitemid 30429175)
4. Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008;123:1991-2006.
5. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999;91:80-5. (Pubitemid 29042447)
6. Willis L, Alarcon T, Elia G, Jones JL, Wright NA, Tomlinson IPM, et al. Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res 2010;70:4310-7.
7. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CRM, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with Stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33. (Pubitemid 30117892)
8. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000;18:80.
9. Mansi JL, Berger U, McDonnell T, Pople A, Rayter Z, Gazet JC, et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 1989;7:445-9. (Pubitemid 19098138)
10. Demicheli R, Terenziani M, Bonadonna G. Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wakeup? Breast Cancer Res Treat 1998;51:133-7.
11. Moharita AL, Taborga M, Corcoran KE, Bryan M, Patel PS, Rameshwar P. SDF-1apha regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. Blood 2006;108:3245-52.
12. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008;8:290-301. (Pubitemid 351432804)
13. Muller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem cell universe. Stem Cells 1995;13:477-86.
14. Dorshkind K. Regulation of hemopoiesis by bone marrow stromal cells and their products. Annu Rev Immunol 1990;8:111-37. (Pubitemid 20135623)
15. 2 distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 2001;81:685-96.
16. Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO2 distributions in the bone marrow hematopoietic compartment. I. Krogh's model. Biophys J 2001;81:675-84.
17. Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 2007;110:3056-63. (Pubitemid 350006961)
18. Sifri ZC, Kaiser VL, Ananthakrishnan P, Wang L, Mohr AM, Hauser CJ, et al. Bone marrow failure in male rats following trauma/hemorrhagic shock (T/HS) is mediated by mesenteric lymph and modulated by castration. Shock 2006;25:12-6.
19. Guest I, Uetrecht J. Drugs toxic to the bone marrow that target the stromal cells. Immunopharmacology 2000;46:103-12. (Pubitemid 30019252)
20. Taback B, Giuliano AE, Hansen NM, Singer FR, Shu S, Hoon DSB. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. Cancer Res 2003;63:1884-7. (Pubitemid 36460853)
21. Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA. Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 2009;23:2592-7.
22. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010;12:247-56.
23. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of Rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009;69:8742-51.
24. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, et al. MicroRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 2010;107:8231-6.
25. Claps CM, Corcoran KE, Cho KJ, Rameshwar P. Stromal derived growth factor-1alpha as a beacon for stem cell homing in development and injury. Curr Neurovasc Res 2005;2:319-29. (Pubitemid 41297369)
26. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 2003;18:1-10. (Pubitemid 38159432)
27. Scherr M, Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 2007;6:444-9. (Pubitemid 46393448)
28. Johnson C, Sundaresan V. Regulatory small RNAs in plants. EXS 2007;97:99-113.
29. Joshi DD, Dang A, Yadav P, Qian J, Bandari PS, Chen K, et al. Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study. Blood 2001;98:2697-706.
30. Ramkissoon SH, Patel PS, Taborga M, Rameshwar P. Nuclear Factor-{kappa}B is central to the expression of truncated neurokinin- 1 receptor in breast cancer: implication for breast cancer cell quiescence within bone marrow stroma. Cancer Res 2007;67:1653-9. (Pubitemid 46383391)
31. Boger DL, Patterson JE, Guan X, Cravatt BF, Lerner RA, Gilula NB. Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc Natl Acad Sci U S A 1998;95:4810-5. (Pubitemid 28208507)
32. Patel SA, Heinrich AC, Reddy BY, Srinivas B, Heidaran N, Rameshwar P. Breast cancer biology: the multifaceted roles of mesenchymal stem cells. J Oncol 2008;2008:article 425895.
33. Greco SJ, Rameshwar P. miRNAs regulate synthesis of the neurotransmitter substance P in human mesenchymal stem cell-derived neuronal cells. Proc Natl Acad Sci U S A 2007;104:15484-9. (Pubitemid 47502943)
34. Rao G, Patel PS, Idler SP, Maloof P, Gascon P, Potian JA, et al. Facilitating role of preprotachykinin-I gene in the integration of breast cancer cells within the stromal compartment of the bone marrow: a model of early cancer progression. Cancer Res 2004;64:2874-81. (Pubitemid 38500628)
35. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008;36:D149-53.
36. Corcoran KE, Fernandes H, Bryan M, Taborga M, Srinivas V, Rameshwar P. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One 2007;3:e2563.
37. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One 2010;5:e9175.
38. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010;12:201.
39. Nie Y, Han YC, Zou YR. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008;205:777-83. (Pubitemid 351549877)
40. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008;15:49-58. (Pubitemid 350191028)
41. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non- Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2009;45:39-47.
42. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006;20:847-56.
43. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70.
44. Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW. Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res 2008;10:R83.